About us Contacts Drug interactions: 390 212
Drug search by name

Tarceva and Zykadia

Determining the interaction of Tarceva and Zykadia and the possibility of their joint administration.

Check result:
Tarceva <> Zykadia
Relevance: 18.10.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme. According to product labeling, coadministration with the potent CYP450 3A4 inhibitor ketoconazole increased erlotinib systemic exposure (AUC) by two-thirds compared to administration of erlotinib alone. MANAGEMENT: Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities. References Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7 "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.

Professional:

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme. According to product labeling, coadministration with the potent CYP450 3A4 inhibitor ketoconazole increased erlotinib systemic exposure (AUC) by two-thirds compared to administration of erlotinib alone.

MANAGEMENT: Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.

References
  • Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7
  • "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.
Tarceva

Generic Name: erlotinib

Brand name: Tarceva

Synonyms: n.a.

Zykadia

Generic Name: ceritinib

Brand name: Zykadia

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction